BSE · 530317
Godavari Drugs Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹114 Cr with net profit ₹4 Cr — a 3.83% net margin, versus 3.53% the period before.
Shareholding
As of 2026-06-30
- Promoter40.23%
- Public57.03%
- DII2.74%
6,722 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.94× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #20 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,06,654 Cr | 274.97 | 12.31 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹27,068 Cr | 205.48 | 16.37 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹25,271 Cr | 118.83 | 13.56 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,568 Cr | 129.46 | 2.18 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,753 Cr | 67.98 | 2.42 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,715 Cr | 110.8 | 4.73 | 12.98% | 11.5% |
| Hikal Limited | ₹2,730 Cr | 189.21 | 2.28 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,264 Cr | 250.08 | 9.25 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,009 Cr | 148.95 | 6.1 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,329 Cr | 67.82 | 3.19 | 17.67% | 13.66% |
| Godavari Drugs Ltd.(this company) | ₹108 Cr | 28.43 | 1.53 | 5.39% | 3.87% |
AI analysis
AI-generated · google/gemini-2.5-flashGodavari Drugs Ltd. is listed with a market capitalization of Rs 121 Cr. The company reported revenue of Rs 114.33 Cr and a profit margin of 386.6%. As of March 31, 2026, promoter holding stood at 40.23% and public holding at 57.30%. The stock is currently under ESM 1 surveillance.
Positives
- +The institutional shareholding, including DIIs, increased from 0% in March 2026 (FII) to 2.47% (DII) in March 2026.
- +Promoter pledge percentage is low at 0.21% of total shares.
Negatives
- −Revenue decreased from Rs 157.33 Cr in Mar 2024 to Rs 114.33 Cr in Mar 2025.
- −Debt-to-equity ratio is 1.48, which indicates high leverage.
- −The company is currently under ESM 1 surveillance.
- −Promoter holding decreased from 40.23% in March 2026 to 0% for FIIs (no FII holding) and from 40.23% to 40.23% for overall promoter holding.
- −Return on Equity (ROE) is 5.39% and Return on Capital Employed (ROCE) is 5.943%, which are relatively low.
Financial Performance
Godavari Drugs Ltd. reported revenue of Rs 114.33 Cr in the latest annual period (Mar 2025). Net profit for the same period was Rs 4.38 Cr, with earnings per share (EPS) at Rs 5.82. Quarterly revenue for Mar 2026 was Rs 33.16 Cr, generating a net profit of Rs 1.29 Cr.
Profitability & Returns
The company recorded a profit margin of 386.6%. Return on equity (ROE) was 5.39% and return on capital employed (ROCE) was 5.943%. The earnings per share (EPS) for the latest annual period was Rs 5.82, while the price-to-earnings (PE) ratio stands at 31.8.
Balance Sheet
Godavari Drugs Ltd. has a debt-to-equity ratio of 1.48. The book value per share is Rs 69.66. The company does not currently offer a dividend, as indicated by a dividend yield of 0%.
Ownership & Pledges
As of March 31, 2026, promoters held 40.23% of the shares. Public shareholding was 57.30%, while DIIs (institutions) held 2.47%. There is a promoter pledge of 0.21% of total shares, specifically 8,531 shares pledged by Kirti Kumar Jain, representing 100% of their holding.
Regulatory & Surveillance
Godavari Drugs Ltd. is currently under 'ESM 1' surveillance, indicating that it is subject to Enhanced Surveillance Measure. This surveillance was initiated due to reasons classified under 'ESM'.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.